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Abstract: FADD (Fas-associated death domain) is the main death receptor adaptor molecule that transmits apoptotic sig-
nal. Recently, FADD protein was shown to be expressed both in the cytoplasm and nucleus of in vitro cell lines. In con-
trast to the cytoplasmic FADD, the nuclear FADD was shown to protect cells from apoptosis. However, in vivo subcellu-
lar localization of FADD was still unknown. Here, we demonstrated that FADD protein was expressed in both cytoplas-
mic and nuclear compartment in ex vivo thyroid cells demonstrating that nuclear sublocalization of FADD protein was a 
relevant phenomenon occurring in vivo. Moreover, we showed that in the nucleus of untransformed thyroid cells FADD 
localized mainly on euchromatin. We confirmed the nuclear localization of FADD in ex vivo liver and showed that in this 
organ FADD and MBD4 interact together. These results demonstrate that FADD is physiologically expressed in the nu-
cleus of cells in at least two mouse organs. This particular localization opens new possible role of FADD in vivo either as 
an inhibitor of cell death, or as a transcription factor, or as a molecular link between apoptosis and genome surveillance. 
Key Words: Fas-associated death domain, Thyroid, Cellular localization, Nucleus, MBD4. 
INTRODUCTION 
 Normal thyrocytes constitutively express the Fas death 
receptor but not the Fas ligand (FasL) [1-3]. However, FasL 
expression in thyroid follicular cells (TFC) can occur under 
numerous thyroid pathological conditions, including auto-
immune diseases and cancer [4-6]. For instance, FasL ex-
pression has been reported in TFC from patients suffering of 
Graves' disease [7] and Hashimoto's thyroiditis [8], the two 
main thyroid autoimmune disorders in humans, and thyroid 
carcinomas [6]. In these pathologies, thyrocytes appear to be 
relatively insensitive to Fas-mediated cell death although 
expressed FasL is functional [9-12]. Reasons for such phe-
nomenon are not clearly established, and probably involve 
several mechanisms such as expression of FLIP (FLICE-
inhibitory protein) and Bcl-xL anti-apoptotic molecules [11], 
or loss of FADD (Fas-associated death domain) pro-
apoptotic protein [13]. Interestingly, normal TFC are natu-
rally resistant to Fas-induced apoptosis suggesting that the 
observed high insensitivity of pathological thyrocytes could 
result from an intrinsic property of normal thyroid cells. 
Since FADD physically interacts with death receptors lo-
cated at the cell membrane, FADD protein was thought to be 
mainly cytoplasmic. Recently, we reported by mean of an in 
vitro organ culture the existence of a new regulatory mecha-
nism of FADD protein expression following adenosine re-
ceptor signaling [14].  
 Furthermore, the human FADD protein contains both a 
nuclear export and a nuclear localization sequence which 
account for FADD localization both in the cytoplasm and the 
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nucleus, respectively [15]. Whereas cytoplasmic FADD pos-
sesses pro-apoptotic functions, it was recently reported that 
FADD expression in the nucleus protects cells from apopto-
sis [15]. The mechanism implicated in this survival function 
has not been investigated.  
 As dogmas can be challenged, FADD nuclear sublocali-
zation has been debated. It was found that FADD primarily 
resided in the nucleus of cells and thereafter shuttled from 
the nucleus to the cytoplasm [16]. In contrast, other report 
showed that FADD was exclusively located in the cytoplasm 
of most adherent and non adherent cell lines [17]. It now 
appears that the discrepancies between these two studies 
likely resulted from different technical approaches [18, 19].  
 Although it is now demonstrated that FADD is expressed 
in the nucleus of both human and mouse cell lines [20], and 
in the nucleus of human lung adenocarcinoma cells [21], no 
data are available concerning the FADD subcellular localiza-
tion in non transformed cell in vivo. Thus, one important 
issue that needed to be clarified was the in vivo FADD sub-
cellular localization. Regarding the innate resistance of TFC 
to apoptosis, and the important role of the Fas pathway in 
thyroid autoimmune and tumoral diseases, we addressed this 
issue in ex vivo mouse thyroid sections. We demonstrated for 
the first time that nuclear localization of FADD protein is not 
a cell line dependent event. We confirmed this result in 
mouse liver and showed that FADD is linked to MBD4 in 
vivo.  
MATERIALS AND METHODS 
Mice 
 Different strains of mice (CBA/J, DBA/1, DBA/2, 
C57BL/6 or BALB/c mice) (Iffa Credo, L’Arbresle, France, 
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and Harlan Olac, Bicester, GB) were used at 7-15 weeks of 
age. All mice were maintained in standard environmental 
conditions, and allowed to adapt to their environment at least 
for one week before the experiments. The studies were ap-
proved by the Cochin institute committee on animal care. 
Agreement number to perform experiments on living ani-
mals: n° 75-777, and animal facility agreement number  
n° 3991. 
Immunofluorescence 
 Animals were sacrificed and the two thyroid lobes re-
moved. Collected lobes were immediately covered in opti-
mal temperature medium (Tissue-Tek; Bayer, Elkhart, IN), 
slowly frozen by floating in isopentane on liquid nitrogen, 
and stored at -80°C until use. Sections of 5–6 m were cut 
on a cryostat at -18°C and collected onto SuperFrostplus 
slides (Roth Sochiel, Lauterbourg, France). Sections were 
dried overnight and stored at -80°C until use. Before stain-
ing, sections were fixed for 15 min in PBS with 2% parafor-
maldehyde (PFA) at 4°C, and incubated for 30 min in PBS 
with 2% bovine serum albumin. Then, sections were stained 
(60 min) with primary goat polyclonal IgG anti-mouse 
FADD antibody (10 g/ml, clone M19, Santa Cruz Biotech-
nology, TebuBio, Le Perray en Yvelines, France) or with 
isotype-matched control antibody at the same concentration 
(Vector Laboratories, AbCys, Paris, France). The secondary 
biotin-conjugated anti-goat IgG antibody (Vector Laborato-
ries) was used at 1 g/ml (30 min). Alexa Fluor 488 conju-
gate streptavidin (10 g/ml, Molecular Probes Inc., Inter-
chim, Montluçon, France) was used to visualize specific 
staining (30 min incubation at room temperature and pro-
tected from light). After washings in PBS, sections were 
mounted in VECTASHIELD Mounting Medium with 
DAPI (4’,6-diamidino-2-phenylindole) (Vector Laboratories) 
to counter-stain DNA. Cells were analyzed by confocal fluo-
rescence microscopy (Bio-Rad
 
MRC1024, Bio-Rad Labora-
tories) equipped with a
 
digital Diaphot 300 system. Digital 
pictures were analyzed using
 
LaserSharp software and proc-
essed using Adobe Photoshop.  
Immunogold Electron Microscopy  
 Thyroid lobes were fixed in 1% glutaraldehyde in 0.1 M 
phosphate buffer pH 7.4, then embedded in sucrose and  
frozen in liquid nitrogen. Cryosections were made using an 
ultracryomicrotome (Reichert Ultracut S.) and ultrathin sec-
tions mounted on Formvar-coated nickel grids were pre-
pared. Briefly, the sections were incubated for 15 min with 
PBS 15% glycine, for 5 min with PBS 15% glycine 0.1% 
BSA and for 20 min with PBS 15% glycine, 0.1% BSA, 10% 
normal donkey serum followed by 2 h incubation with the 
goat polyclonal anti-FADD antibody M19. The primary  
antibodies were diluted to 2 g/ml in PBS 15% glycine, 
0.1% BSA, 4% normal donkey serum. After extensive rins-
ing in PBS 15% glycine, 0.1% BSA, sections were incubated 
for 1 h with gold-labeled secondary rabbit anti-goat antibody 
with a gold particle size of 10 nm (GAM 10, British Biocell, 
Cardiff, Wales). Sections were then washed for 30 min with 
PBS 15% glycine, stained with 2% uranyl acetate for 10 min 
and air dried. Examination was performed with a Philips CM 
10 electron microscope.  
Preparation of Protein Extracts 
 Proteins of ex vivo mouse liver were extracted with the 
Nuclear Extract Kit (Active Motif, Europe, Rixensarf, Bel-
gium) following manufacturer’s instructions. Sample con-
centration was determined using micro BCA protein assay 
reagent kit (Pierce , Rockford, IL, USA). 
Immunoprecipitation  
 The nuclear extracts were precleared with proteins G 
sepharose (P-3296, Sigma-Aldrich chimie SARL, Saint 
Quentin Fallavier, France) on rocking for 1 h at 4°C. Then, 1 
g of either rabbit polyclonal anti-FADD (AB3102, Chemi-
con International, Temecula, CA, USA), or rabbit polyclonal 
anti-MBD4 (ab3756, abcam,Cambridge, United Kingdom), 
or isotype-matched control antibody (normal rabbit IgG, 
Santa Cruz Biotechnology) was added at the precleared nu-
clear extracts, and the mix were incubated for 2 h on ice. 
Thereafter, 16 g of clear proteins G sepharose was added. 
After an additional 2 h on rotating wheel at 4ºC, precipitates 
were washed five times with 500 l of lysis buffer (10 mM 
Tris HCl pH 7.8, 150 mM NaCl, 1% NP40, a protease cock-
tail inhibitor set (complete Mini EDTA-Free, Roche, Indian-
apolis, USA)). Then, immunoprecipitates were analyzed by 
FADD specific western blotting. 
Western Blot 
 40 g of cytoplasmic or nuclear proteins, and the im-
munoprecipitates were diluted in reducing sample buffer, 
subjected to 15 % SDS-PAGE, transferred to PVDF mem-
brane (NEN Life Sciences, Boston, Massachusetts), and 
probed with specific primary anti-FADD antibody (M-19, 
0.2 g/ml in TTBS 0.1% containing 5% milk) (Santa Cruz 
Biotechnology) following by peroxidase-conjugated anti-
goat IgG (0.66 g/ml) secondary antibody (Sigma-Aldrich). 
Proteins were visualized using the enhanced chemilumines-
cence technique (Amersham Pharmacia Biotech, Orsay, 
France). Bands obtained were quantified by densitometry 
using biocapt and bio-profil bio1d software. The same 
amount of nuclear proteins and cytoplasmic proteins were 
loaded on gel although the total amount of nuclear protein 
was five to ten times lesser than the amount of cytoplasmic 
proteins.  
RESULTS AND DISCUSSION 
 Animals were sacrificed and the thyroid removed. The 
two thyroid lobes were either immediately covered in opti-
mal temperature embedding medium for immunofluores-
cence analysis (Fig. 1), or immediately fixed with glutaral-
dehyde for immunogold electron microscopy (Fig. 2). To 
avoid the problems associated with permeabilization rea-
gents such as saponin [18, 19], we performed thyroid cryo-
sections that we immunolabeled with the previously charac-
terized specific anti-mouse FADD antibody [13].  
 Confirming our previous study [13], confocal immuno- 
fluorescence microscopy analysis showed that FADD protein 
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was expressed in the cytoplasm of all TFC (Fig. 1a,e,g), and 
in all thyroid examined independently of the genetic back-
ground of the mice (data not shown). Moreover, we observed 
that FADD was additionally localized in the nucleus of 
some, but not all, TFC (Fig. 1a,b,e-g). In contrast, omission 
of the primary antibody or staining with an isotype-matched 
control antibody showed no positive reactivity in the nucleus 
(Fig. 1c,d,h-j, and data not shown). To confirm these results, 
and to localize more precisely the FADD protein in TFC, we 
used immunogold electron microscopy. This method allowed 
us to detect FADD protein both in the cytoplasm and in the 
nucleus of TFC (Fig. 2a and b), confirming the results ob-
tained by confocal microscopy. Furthermore, the electron 
microscopy technique showed that FADD was expressed in 
the nuclear compartment of all the TFC examined (data not 
shown).  
 The different cell-types in tissue samples provided useful 
internal comparators, when assessing FADD immunolabel-
ing. We found that FADD protein was not, or barely detected 
in the nucleus of endothelial cells from blood vessel which 
are localized between thyroid follicles (Fig. 2e and f). Since 
FADD was present in the nucleus of ex vivo mouse thyroid 
cells, our data demonstrated that nuclear localization of 
FADD protein was not an in vitro culture cell line dependent 
event. However, the TFC restricted pattern of expression of 
nuclear FADD protein in thyroid gland suggested that nu-
clear sublocalization of this protein may not be a common 
feature and may depend on cell type. Finally, we confirmed 
that FADD could be expressed in the nucleus of cells in vivo 
using a third approach which is cellular fractionation. Be-
cause of the large amount of protein needed for such technic, 
we used proteins of ex vivo mouse liver instead of thyroid. 
We chose liver to compare with thyroid because both hepa-
tocytes and thyrocytes are epithelial cells. Whatever the 
amounts of protein extracts loaded on SDS-PAGE, we de-
tected FADD expression both in the cytoplasmic and nuclear 
fractions (Fig. 3a). Quantification of bands obtained by 
western blot showed that the nuclear FADD represents one 
third of the total FADD protein, demonstrating that in this 
organ FADD is mainly cytoplasmic (Fig. 3b). These results 
confirmed that FADD is present in the nucleus of two types 
of mouse epithelial cells in vivo.  
 We observed that part of FADD was localized in the nu-
cleus. This result differed from several results reporting the 
nuclear localization of only a minor fraction of FADD. On 
the other hand it was in line with the results reported in ad-
herent cell lines in which FADD seems to primarily reside in 
the nucleus, and thereafter to translocate to the cytoplasm 
[16] a phenomenon which depends on phosphorylation at 
serine 194. Here in we estimated that in our setting around 
20% of the total FADD was localized in the nucleus.  
 FADD is a complex molecule and some of its assigned 
properties have not been yet fully demonstrated. For in-
stance, the death effector filaments (DEF) structures are cy-
toplasmic filament network composed of death effector do-
main (DED)-containing proteins, including FADD [22], that 
recruit and activate pro-caspase 8 [23]. However, the exis-
tence of DEF has not been established in vivo, and increasing 
evidences suggest that DEF could be structures resulting 
only from protein over-expression [15, 16]. Indeed, DEF 
formation has always been observed in the context of FADD 
protein over-expression, and DEF have been characterized as 
detergent-insoluble in contrast to endogenous FADD which 
is soluble in NP40 or triton. Here, we demonstrated that the 
ability of FADD to localize in the nuclear compartment is  
a natural phenomenon since it occurred in primary normal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Analysis of FADD subcellular localization by im-
munofluorescence confocal microscopy. (a, e) Ex vivo thyroid sec-
tions were stained with anti-FADD antibody (green fluorescence). 
(c, h) Staining of thyroid sections with Alexa Fluor 488 anti-goat 
antibody alone showed no positive reactivity. The same result was 
obtained using isotype-matched control antibody (data not shown). 
(b, d, f, i) Nucleus of TFC were counter-stained with DAPI (blue 
fluorescence). (g, j) FADD immunolabelling and DAPI merge. Co: 
colloid; Cy: cytoplasm; N: nucleus. Bars indicate scale.  
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cells ex vivo. Moreover, we showed that FADD protein lo-
calized in the nucleus of thyrocytes and liver cells in physi-
ologic conditions as well as in the cytoplasm, demonstrating 
that in vivo FADD does not have exclusive subcellular local-
ization in these two cell types.  
 The function of nuclear FADD, in contrast to the well 
established role of cytoplasmic FADD in cell death [24, 25], 
is poorly understood. Whereas FADD interaction with death 
receptors activates caspase activation cascade in the cyto-
plasm, thus leading to the apoptotic death of the cell, nuclear 
FADD appears to be implicated in survival mechanisms 
[15]. It has been suggested that sequestration of FADD in the 
nucleus could protect cells from apoptosis by hindering 
FADD-triggered caspase interactions in the cytoplasm [16]. 
Indeed, it has been demonstrated in cell line that the methyl-
CpG binding domain protein 4 (MBD4) could interact with 
FADD in the nucleus. The relative level of FADD, MBD4, 
and caspase 8 may determine the apoptotic output of the 
cells. Here in, we tested if FADD could interact with MBD4 
in vivo. We performed coimmunoprecipitation experiments 
using rabbit polyclonal anti-MBD4 or anti-FADD antibod-
ies, and revealed the presence of FADD protein by specific 
western blotting. We could not perform the converse ex-
periment since the anti-MBD4 did not work well for western 
blot detection. Immunoprecipitates obtained from nuclear 
extract of liver cells contained a FADD signal, in contrast to 
those obtained with isotype-matched control rabbit IgG (Fig. 
4). The anti-FADD antibody did not allow immunoprecipita-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Analysis of FADD subcellular localization by immunogold electron microscopy. FADD (indicated by arrowheads) is found both in 
the cytoplasm and the nucleus of TFC (a-d) but not in the nucleus of endothelial cells from blood vessel (e, f). c, d, and f represent higher 
magnification of b and e, respectively (see framed). Staining with secondary anti-goat antibody alone or isotype-matched control antibody 
showed no immunogold deposition (data not shown). Co: colloid; Cy: cytoplasm; N: nucleus; RBC: red blood cell. Bars indicate scale.  
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tion of all the nuclear FADD since the protein was still de-
tected in the supernatant after immunoprecipitation (Fig. 
4A). By contrast, all the nuclear FADD was immunoprecipi-
tated by the anti-MBD4 antibody demonstrated that all the 
nuclear FADD was bound to MBD4 (Fig. 4a).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Analysis of FADD subcellular localization by western blot 
after cellular fractionation. (a) Western blot was performed using 
different amount of protein extracts from ex vivo liver, as noted in 
the figure. (b) Histogram represents quantification of bands  
obtained in (a). Results are expressed in arbitrary units. Full and 
empty histograms represent cytoplasmic and nuclear fractions,  
respectively.  
 These results demonstrated that FADD interacts with 
MBD4 in vivo. This interaction by contributing to FADD 
sequestration in the nucleus could be involved in protection 
of cells from death receptor-mediated apoptosis. Alterna-
tively, knowing the key role of MBD4 in GT mismatches 
repair [26], MBD4-FADD interaction could link genome 
surveillance/DNA repair and apoptosis in liver cells in vivo.  
 On the other hand, FADD could be a transcription factor 
which could induce anti-apoptotic gene expression [15]. In-
terestingly, using immunogold electron microscopy we ob-
served in the nucleus of TFC that the FADD protein local-
ized almost exclusively on euchromatin, i.e. noncondensed 
DNA (Fig. 2b-d). This particular localization was observed 
in nucleus of all TFC (data not shown). These results are in 
favor of FADD playing a role as a regulator of transcription 
in thyroid cells. Now that we have demonstrated the dual 
subcellular localization of FADD in TFC, further experi-
ments are needed to determine whether nuclear FADD is a 
real transcription factor and whether it might regulate ex-
pression of anti-apoptotic gene, in particular in pathological 
TFC. This could contribute to the high resistance of TFC to 
death receptor-mediated cell death despite the concomitant 
presence of FADD in the cytoplasm [2, 13]. Characterization 
of potential FADD-DNA binding sequences or FADD-
protein binding partners in nucleus might provide keys for 
this concept.  
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Fig. (4). FADD interacts with MBD4 in vivo. (a) Western blot analysis of FADD in the cytoplasm (C) and nucleus (N) of ex vivo liver.  
Nucleus lysates was immunoprecipitated (IP) with isotype-matched control (ctrl), anti-FADD (FADD), or anti-MBD4 (MBD4) antibodies. 
Immunoprecipitates were analyzed by FADD specific western blotting.  (b) Histogram represents quantification of bands obtained in (a) 
after normalization to adjust the amount of proteins loaded to 40 g. Results are expressed in arbitrary units.  
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